Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy

Author： Breccia Massimo Lo-Coco Francesco

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.11, Iss.2, 2011-02, pp. : 225-234

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia

By Hütter Marie-Luise Schlenk Richard F

Expert Opinion on Biological Therapy, Vol. 11, Iss. 10, 2011-10 ,pp. : 1369-1380

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse

By Sievers Eric L

Expert Opinion on Biological Therapy, Vol. 1, Iss. 5, 2001-09 ,pp. : 893-901

Informa Healthcare

Access to resources Recommend Favorite

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

By Stasi Roberto

Expert Opinion on Biological Therapy, Vol. 8, Iss. 4, 2008-04 ,pp. : 527-540

Informa Healthcare

Access to resources Recommend Favorite

The efficacy and safety of golimumab in the treatment of arthritis

By Fleischmann Roy

Expert Opinion on Biological Therapy, Vol. 10, Iss. 7, 2010-07 ,pp. : 1131-1143

Informa Healthcare

Access to resources Recommend Favorite

Oxidative stress enhances granulocytic differentiation in HL 60 cells, an acute promyelocytic leukemia cell line

By Ogino Tetsuya Ozaki Michitaka Matsukawa Akihiro

Free Radical Research, Vol. 44, Iss. 11, 2010-11 ,pp. : 1328-1337

Informa Healthcare

Access to resources Recommend Favorite